China's biotechnology services company announced that it has signed an agreement with Stella Pharma for the commercialization of boron neutron capture therapy drugs in China.

China Biotechnology Services: The Group has entered into a main cooperation agreement with Stella Pharma to jointly promote the development and commercialization of Steboronine in China. This collaboration creates a synergistic effect with the Group's flagship project, the Pengbo Hainan Boron Neutron Hospital, marking an important strategic move for the Group to introduce advanced boron neutron therapy technology into the Chinese market, aiming to further solidify and expand its business in China.